Document is current
Any future updates will be listed below
-
Authors
Rassy, Elie
Benvenuti, Chiara
Akla, Sarra
Di Meglio, Antonio
Martin, Elise
Havas, Julie
Rieutord, André
Combarel, David
Fasse, Léonor
Scotté, Florian
Guéroult Accolas, Laure
Jacob, Guillemette
Bergougnoux, Anne
Delaloge, Suzette http://orcid.org/0000-0003-2106-9165
Vaz-Luis, Ines http://orcid.org/0000-0002-7194-2260
Pistilli, Barbara http://orcid.org/0000-0002-9184-7199
- License Information
-
More Information
Article History
Received: 30 January 2024
Accepted: 1 June 2024
First Online: 17 June 2024
Competing interests
: E.R.: Honoraria: Eli Lilly, Seagen, and Novartis ; Travel, Accommodations, Expenses: Pfizer, Roche, Mundipharma, Eli Lilly, Gilead, and Novartis; Grants: Gilead (institutional). A.D.M.: Expert Testimony: Kephren, Medycis, Techspert. L.F.: Personal fees: Pierre Fabre, Grünenthal GmbH; Research Funding: GlaxoSmithKline Biologicals, IPSEN, AMGEN. I.V.L.: Honoraria: AstraZeneca (Inst), Amgen (Inst), Pfizer (Inst), Novartis (Inst), Sandoz (Inst); Research Funding: Resilience (Inst), Travel: Novartis. B.P.: Consulting/Advisor: Puma Biotechnology, Novartis, Myriad Genetics, Pierre Fabre; Personal fees: Novartis, AstraZeneca, MSD Oncology, Pfizer; Research funding: Daiichi-Sankyo, Puma Biotechnology, Novartis, Merus, Pfizer, AstraZeneca. The remaining authors declare no competing interests.
